To order this 450+ page report, which features 120+figures and 140+ tables, please visit this link
KeyMarket Insights
§ Over 80 companies are offering antibody discovery services;of these, more than 75 players claim to offer services related to hitgeneration.
§ Nearly 180 innovative technology platforms have beendeveloped by numerous firms for the purpose of antibody discovery.
§ Majority of stakeholders in the competitive marketlandscape are small / mid-sized firms, catering to the needs of a diverseclientele.
§ In order to get an edge over their competitors in the industry,companies have established their presence in different regions across the globe.
§ The rising interest in this fieldis reflected in the number of partnerships inked in the recent past, involvingboth international and indigenous stakeholders, and focused on antibodydiscovery for diverse range of indications.
§ Efforts of the players in the field of antibody discoveryhave garnered significant interest of several venture capital investors.
§ The antibody discovery services marketis expected to witness growth at a CAGR of ~10%; the anticipated opportunity islikely to be distributed across various steps involved in antibody discovery, antibodydiscovery method, nature of antibody generated and geographies.
§ The market for antibody discovery platforms is currentlybeing driven by the revenues from the licensing deals; it is anticipated toreach USD 5.9 billion by 2030.
For more information, please visit https://www.rootsanalysis.com/reports/view_document/antibody-discovery-services-and-platforms/213.html
Table of Contents
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Structure of Antibodies
3.3. History of Development
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Classification of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Polyclonal Antibodies
3.6.3. Bispecific Antibodies
3.7. Applications of Antibodies
Press Release:Variation 2 (Format 3)
4. ANTIBODY DISCOVERY PROCESS AND METHODS
4.1. Chapter Overview
4.2. Antibody Discovery Process
4.2.1. Target Selection and Validation
4.2.2. Hit Generation
4.2.3. Lead Selection
4.2.4. Lead Optimization
4.2.4.1. Humanization
4.2.4.2. Affinity Maturation
4.2.4.3. Fc Engineering
4.2.5. Lead Characterization
4.2.6. Candidate Selection
4.3. Antibody Discovery Methods
4.3.1. Hybridoma Method
4.3.2. In vitro Display Method
4.3.2.1. Phage Display
4.3.2.2. Yeast Display
4.3.2.3. Ribosomal Display
4.3.3. Transgenic Animal-Based Method
4.3.4. Single B Cell-Based Method
4.3.5. Advantages and Disadvantages of ExistingAntibody Discovery Techniques
4.4. Evolution of Monoclonal Antibodies
4.4.1. Fully Human Monoclonal Antibodies
5. ANTIBODY DISCOVERY SERVICE PROVIDERS:CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Antibody Discovery Service Providers:List of Industry Players
5.2.1. Analysis by Year of Establishment
5.2.2. Analysis by Company Size
5.2.3. Analysis by Location of Headquarters
5.2.4. Analysis by Type of Service Offered
5.2.5. Analysis by Type of Antibody DiscoveryMethod
5.2.6. Grid Representation: Analysis by Type ofService Offered, Type of Antibody Discovery Method and Company Size
5.2.7. Analysis by Animal Model Used
5.2.8. Analysis by Type of Antibody Discovered
5.2.9. Analysis by Type of Antibody DiscoveryMethod and Type of Antibody Discovered
5.2.10. Analysis by Purpose of Antibody Discovery
5.2.11. Analysis by Type of Antibody Discovery Methodand Purpose of Antibody Discovery
6. COMPANY COMPETITIVENESS ANALYSIS
6.1. Chapter Overview
6.2. Methodology
6.3. Key Parameters
6.4. Competitiveness Analysis: AntibodyDiscovery Service Providers
6.4.1. Antibody Discovery Service Providers basedin North America
6.4.2. Antibody Discovery Service Providers basedin Europe
6.4.3. Antibody Discovery Service Providers basedin Asia Pacific
7. COMPANY PROFILES: ANTIBODY DISCOVERYSERVICE PROVIDERS
7.1. Chapter Overview
7.2. Antibody Discovery Service Providers inNorth America
7.2.1. Abwiz Bio
7.2.1.1. Company Overview
Press Release:Variation 2 (Format 3)
7.2.1.2. Antibody Discovery Services
7.2.1.3. Recent Developments and Future Outlook
7.2.2. Aragen Bioscience (A GVK BIO Company)
7.2.2.1. Company Overview
7.2.2.2. Antibody Discovery Services
7.2.2.3. Recent Developments and Future Outlook
7.2.3. Distributed Bio
7.2.3.1. Company Overview
7.2.3.2. Antibody Discovery Services
7.2.3.3. Recent Developments and Future Outlook
7.2.4. Integral Molecular
7.2.4.1. Company Overview
7.2.4.2. Antibody Discovery Services
7.2.4.3. Recent Developments and Future Outlook
7.2.5. LakePharma
7.2.5.1. Company Overview
7.2.5.2. Antibody Discovery Services
7.2.5.3. Recent Developments and Future Outlook
7.3. Antibody Discovery Service Providers inEurope
7.3.1. Abzena
7.3.1.1. Company Overview
7.3.1.2. Financial Information
7.3.1.3. Antibody Discovery Services
7.3.1.4. Recent Developments and Future Outlook
7.3.2. ImmunoPrecise Antibodies
7.3.2.1. Company Overview
7.3.2.2. Financial Information
7.3.2.3. Antibody Discovery Services
7.3.2.4. Recent Developments and Future Outlook
7.3.3. PX'Therapeutics (Subsidiary of AguettantPharmaceutical Group)
7.3.3.1. Company Overview
7.3.3.2. Antibody Discovery Services
7.3.3.3. Recent Developments and Future Outlook
7.4. Antibody Discovery Service Providers inAsia-Pacific
7.4.1. ChemPartner
7.4.1.1. Company Overview
7.4.1.2. Antibody Discovery Services
7.4.1.3. Recent Developments and Future Outlook
7.4.2. Viva Biotech
7.4.2.1. Company Overview
7.4.2.2. Financial Information
7.4.2.3. Antibody Discovery Services
7.4.2.4. Recent Developments and Future Outlook
7.4.3. WuXi Biologics
7.4.3.1. Company Overview
7.4.3.2. Financial Information
Press Release:Variation 2 (Format 3)
7.4.3.3. Antibody Discovery Services
7.4.3.4. Recent Developments and Future Outlook
8. ANTIBODY DISCOVERY TECHNOLOGIES:CURRENT MARKET LANDSCAPE
8.1. Chapter Overview
8.2. Antibody Discovery Platform Providers:List of Industry Players
8.2.1. Analysis by Year of Establishment
8.2.2. Analysis by Company Size
8.2.3. Analysis by Location of Headquarters
8.2.4. Analysis by Type of Antibody Discovered
8.3. Antibody Discovery: List of Technologiesand Platforms
8.3.1. Analysis by Type of Antibody DiscoveryMethod
8.3.2. Analysis by Type of Antibody DiscoveryMethod and Location of Headquarters
8.3.3. Analysis by Animal Model Used
8.3.4. Analysis by Patent Availability
9. TECHNOLOGY COMPETITIVENESS ANALYSIS
9.1. Chapter Overview
9.2. Methodology
9.3. Key Parameters
9.4. Technology Competitiveness Analysis:Antibody Discovery Platforms
9.4.1. Competitiveness Analysis: Library BasedAntibody Discovery Platforms
9.4.2. Competitiveness Analysis: Single Cell BasedAntibody Discovery Platforms
9.4.3. Competitiveness Analysis: Transgenic AnimalBased Antibody Discovery Platforms
9.4.4. Competitiveness Analysis: Other AntibodyDiscovery Platforms
10. COMPANY PROFILES: ANTIBODY DISCOVERYPLATFORM PROVIDERS
10.1. Chapter Overview
10.2. ImmunoPrecise Antibodies
10.2.1. Company Overview
10.2.2. Financial Information
10.2.3. Portfolio of Antibody Discovery Platforms
10.2.3.1.Abthena™
10.2.3.2.B cell Select™
10.2.3.3.DeepDisplay™
10.2.3.4.ModiFuse™
10.2.3.5.ModiPhage™
10.2.3.6.ModiSelect™
10.2.3.7.ModiTune™
10.2.4. RecentDevelopments and Future Outlook
10.3. Harbour BioMed
10.3.1. Company Overview
10.3.2. Portfolio of Antibody Discovery Platforms
10.3.2.1.H2L2 Platform
10.3.2.2.HCAb Platform
10.3.3. RecentDevelopments and Future Outlook
10.4. Kymab
10.4.1. Company Overview
10.4.2. Portfolio of Antibody Discovery Platforms
10.4.2.1.Kymouse™
10.4.2.2.IntelliSelect®
10.4.3. RecentDevelopments and Future Outlook
10.5. Ligand Pharmaceuticals
Press Release:Variation 2 (Format 3)
10.5.1. Company Overview
10.5.2. Financial Information
10.5.3. Portfolio of Antibody Discovery Platforms
10.5.3.1.OmniAb®
10.5.3.1.1.OmniChicken®
10.5.3.1.2.OmniClic™
10.5.3.1.3.OmniFlic®
10.5.3.1.4.OmniMouse®
10.5.3.1.5.OmniRat®
10.5.4. Recent Developments and Future Outlook
10.6. MorphoSys
10.6.1. Company Overview
10.6.2. Financial Information
10.6.3. Portfolio of Antibody Discovery Platforms
10.6.3.1.arYla® Technology
10.6.3.2.HuCAL® Technology
10.6.3.3.Ylanthia® Technology
10.6.4. Recent Developments and Future Outlook
11. REGIONAL CAPABILITY ANALYSIS
11.1. Chapter Overview
11.2. Key Assumptions and Methodology
11.3. Regional Capability Analysis: AntibodyDiscovery Service Providers
11.3.1. Regional Capability Analysis: Distribution ofAntibody Discovery Service Providers based in North America
11.3.2. Regional Capability Analysis: Distribution ofAntibody Discovery Service Providers based in Europe
11.3.3. Regional Capability Analysis: Distribution ofAntibody Discovery Service Providers based in Asia-Pacific
11.4. Regional Capability Analysis: AntibodyDiscovery Platform Providers
11.4.1. Regional Capability Analysis: Distribution ofAntibody Discovery Platform Providers based in North America
11.4.2. Regional Capability Analysis: Distribution ofAntibody Discovery Platform Providers based in Europe
11.4.3. Regional Capability Analysis: Distribution ofAntibody Discovery Platform Providers based in Asia-Pacific
11.5. Concluding Remarks
12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by the Type of Company (Service / PlatformProviders)
12.3.4. Analysis by Type of Antibody Discovered
12.3.5. Analysis by Year of Partnership and Type ofPartner
12.3.6. Analysis by Type of Partnership and Type ofPartner
12.3.7. Most Active Players: Analysis by Number ofPartnerships
12.3.8. Most Popular Technologies: Analysis by Numberof Partnerships
12.3.9. Regional Analysis
12.3.9.1.Intercontinental and Intracontinental Agreements
Press Release:Variation 2 (Format 3)
13. FUNDING AND INVESTMENT ANALYSIS
13.1. Chapter Overview
13.2. Types of Funding
13.3. Antibody Discovery Service and PlatformProviders: Funding and Investment Analysis
13.3.1. Analysis by Number of Instances
13.3.2. Analysis by Amount Invested
13.3.3. Analysis by Type of Funding
13.3.4. Most Active Players: Analysis by AmountInvested
13.3.5. Most Active Investors: Analysis by Number ofFunding Instances
13.3.6. Regional Analysis by Amount Invested
13.4. Concluding Remarks
14. ANTIBODY DISCOVERY SERVICES: MARKETFORECAST
14.1. Chapter Overview
14.2. Forecast Methodology
14.3. Global Antibody Discovery Services Market,2020-2030
14.4. Global Antibody Discovery Services Market:Distribution by Steps Involved in Antibody Discovery Process, 2020-2030
14.4.1. Antibody Discovery Services Market forAntigen Designing, 2020-2030
14.4.2. Antibody Discovery Services Market for HitGeneration, 2020-2030
14.4.3. Antibody Discovery Services Market for LeadSelection, 2020-2030
14.4.4. Antibody Discovery Services Market for LeadOptimization, 2020-2030
14.4.5. Antibody Discovery Services Market for LeadCharacterization, 2020-2030
14.5. Global Antibody Discovery Services Market:Distribution by Antibody Discovery Method, 2020-2030
14.5.1. Antibody Discovery Services Market for PhageDisplay, 2020-2030
14.5.2. Antibody Discovery Services Market for YeastDisplay, 2020-2030
14.5.3. Antibody Discovery Services Market forHybridoma Method, 2020-2030
14.5.4. Antibody Discovery Services Market forTransgenic Animal Based Method, 2020-2030
14.5.5. Antibody Discovery Services Market for SingleCell Based Method, 2020-2030
14.5.6. Antibody Discovery Services Market for OtherMethods, 2020-2030
14.6. Global Antibody Discovery Services Market:Distribution by Nature of Antibody Generated, 2020-2030
14.6.1. Antibody Discovery Services Market forHumanized Antibodies, 2020-2030
14.6.2. Antibody Discovery Services Market for HumanAntibodies, 2020-2030
14.6.3. Antibody Discovery Services Market forChimeric Antibodies, 2020-2030
14.6.4. Antibody Discovery Services Market for MurineAntibodies, 2020-2030
14.7. Global Antibody Discovery Services Market:Distribution by Region, 2020-2030
14.7.1. Antibody Discovery Services Market in NorthAmerica, 2020-2030
14.7.2. Antibody Discovery Services Market in Europe,2020-2030
14.7.3. Antibody Discovery Services Market inAsia-Pacific and Rest of the World, 2020-2030
14.7.4. Antibody Discovery Services: Market AttractivenessAnalysis by Region
15. ANTIBODY DISCOVERY TECHNOLOGIES: MARKETFORECAST
15.1. Chapter Overview
15.2. Key Assumptions
15.3. Forecast Methodology
15.4. Global Antibody Discovery PlatformsMarket, 2020-2030
15.5. Global Antibody Discovery PlatformsMarket: Distribution by Region, 2020-2030
15.5.1. Antibody Discovery Platforms Market in NorthAmerica, 2020-2030
15.5.2. Antibody Discovery Platforms Market inEurope, 2020-2030
15.5.3. Antibody Discovery Platforms Market inAsia-Pacific, 2020-2030
16. CASE IN POINT: DRUG DISCOVERY PROCESSESOF TOP SELLING ANTIBODIES
16.1. Chapter Overview
Press Release:Variation 2 (Format 3)
16.2. Humira® (Adalimumab)
16.2.1. Drug Overview
16.2.2. Discovery Process and Method
16.2.3. Historical Sales
16.3. Keytruda® (Pembrolizumab)
16.3.1. Drug Overview
16.3.2. Discovery Process and Method
16.3.3. Historical Sales
16.4. Herceptin® (Trastuzumab)
16.4.1. Drug Overview
16.4.2. Discovery Process and Method
16.4.3. Historical Sales
16.5. Avastin® (Bevacizumab)
16.5.1. Drug Overview
16.5.2. Discovery Process and Method
16.5.3. Historical Sales
16.6. Rituxan® (Rituximab)
16.6.1. Drug Overview
16.6.2. Discovery Process and Method
16.6.3. Historical Sales
17. CASE STUDY: ANTIBODY HUMANIZATION ANDAFFINITY MATURATION
17.1. Importance of Antibody Humanization andAffinity Maturation
17.2. Antibody Humanization and AffinityMaturation Service and Platform Providers: Market Landscape
17.3. Antibody Humanization: PublicationAnalysis
17.3.1. Publication Analysis: Year-Wise Trend
17.3.2. Publication Analysis: Key Journals
17.3.3. Publication Analysis: Distribution by AnimalModel Used
17.3.4. Publication Analysis: Distribution by MethodUsed for Humanization
17.4. Antibody Humanization Service and PlatformProviders: SWOT Analysis
18. FUTURE GROWTH OPPORTUNITIES IN ANTIBODYDISCOVERY
18.1. Chapter Overview
18.2. Anticipated Shift from MonoclonalAntibodies to Other Novel Formats
18.3. Technological Advancements to OverhaulConventional Antibody Discovery Processes
18.4. Transition to CADD-based Approaches toHelp Achieve Better Operational Efficiencies
18.5. Rising Demand for Antibody-based TreatmentOptions across Non-Oncology Indications
18.6. Growing Market Opportunities in theAsia-Pacific Region
18.7. Expected Increase in Number ofCollaborations and Licensing Activity
18.8. Concluding Remarks
19. EXECUTIVE INSIGHTS
19.1. Chapter Overview
19.2. Abveris Antibody
19.2.1. Company Snapshot
19.2.2. Tracey Mullen, Chief Executive Officer (Q22020)
19.3. Nidus Biosciences
19.3.1. Company Snapshot
19.3.2. Lisa Delouise, Founder and Chief TechnologyOfficer (Q1 2020)
Press Release:Variation 2 (Format 3)
19.4. AvantGen
19.4.1. Company Snapshot
19.4.2. Mark Kubik, Chief Business Officer (Q1 2020)
19.5. Single Cell Technology
19.5.1. Company Snapshot
19.5.2. Chun-Nan Chen, Chief Executive Officer andChief Scientific Officer (Q2 2018)
19.6. Distributed Bio
19.6.1. Company Snapshot
19.6.2. Giles Day, Co-Founder and Chief ExecutiveOfficer (Q2 2018)
19.7. AbCellera
19.7.1. Company Snapshot
19.7.2. Kevin Heyries, Co-Founder and Lead ofBusiness Development Strategy (Q2 2018)
19.8. AbGenics Life Sciences
19.8.1. Company Snapshot
19.8.2. Sanjiban K Banerjee, Director (Q2 2018)
19.9. CDI Laboratories
19.9.1. Company Snapshot
19.9.2. Ignacio Pino, Chief Executive Officer andPresident (Q2 2017)
19.10. AP Biosciences
19.10.1.Company Snapshot
19.10.2.Jeng Her, Chief Executive Officer (Q2 2017)
19.11. YUMAB
19.11.1.Company Snapshot
19.11.2.Thomas Schirrmann, Chief Executive Officer and General Manager (Q2 2017)
19.12. Antibody Solutions
19.12.1.Company Snapshot
19.12.2.Debra Valsamis, Business Development Associate (Q2 2017)
19.13. Ligand Pharmaceuticals
19.13.1.Company Snapshot
19.13.2.Christel Iffland, Vice President (Q2 2017)
19.14. LakePharma
19.14.1.Company Snapshot
19.14.2.Aaron Sato, Chief Scientific Officer (Q2 2017)
20. CONCLUDING REMARKS
20.1. Chapter Overview
20.2. Key Takeaways
21. APPENDIX 1: TABULATED DATA
22. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Gaurav Chaudhary
+1 (415) 800 3415
Gaurav.Chaudhary@rootsanalysis.com
